Egyptian practical guidance in hypertriglyceridemia management 2021

• Published in: The Egyptian heart journal Vol. 73; no. 1; pp. 107 - 10
• Main Authors: Taha, Hesham Salah El Din, Kandil, Hossam, Farag, Nabil, Oraby, Abbas, Sharkawy, Magdy El, Fawzy, Fouad, Mahrous, Hossam, Bahgat, Juliette, Samy, Mina, Aboul, Mohamed, Abdrabou, Mostafa, Shaker, Mirna Mamdouh
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 20.12.2021; Springer; Springer Nature B.V; SpringerOpen
• Subjects: Atherosclerosis; Atherosclerotic cardiovascular disease; Cardiology; Cardiovascular disease; Cardiovascular diseases; Care and treatment; Cholesterol; Chronic illnesses; Diabetes; Disease prevention; Dyslipidemia; Family medical history; High density lipoprotein; Hyperlipidemia; Hypertriglyceridemia; Kidney diseases; Lifestyles; Lipids; Lipoproteins; Low density lipoproteins; Medicine; Medicine & Public Health; Metabolic disorders; Metabolic syndrome; Pancreatitis; Patients; Practical guidance; Review; Statins; Strategic planning (Business); Triglycerides; Egypt; Practical guidance; Atherosclerotic cardiovascular disease; Hypertriglyceridemia; Dyslipidemia
• ISSN: 2090-911X; 1110-2608; 2090-911X
• DOI: 10.1186/s43044-021-00235-9

Hypertriglyceridemia (HTG) is a very common, yet underappreciated problem in clinical practice. Elevated triglyceride (TG) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, severe HTG may lead to acute pancreatitis. Although LDL-guided statin therapy has improved ASCVD outcomes, residual risk remains. Recent trials have demonstrated that management of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events. Few guidelines were issued, providing important recommendations for HTG management strategies. The goal of treatment is to reduce the risk of ASCVD and acute pancreatitis. The management stands on lifestyle modification, detection of secondary causes of HTG and pharmacological therapy, when indicated. In this guidance we review the causes and classification of HTG and summarize the current methods for risk estimation, diagnosis and treatment. The present guidance provides a focused update on the management of HTG, outlined in a simple user-friendly format, with an emphasis on the latest available data.